河南太龙药业股份有限公司2025年度向特定对象发行A股股票预案

Core Viewpoint - The company plans to issue A-shares to a specific entity, Jiangyao Holdings, to strengthen its capital structure and control, while also enhancing its operational capabilities in the pharmaceutical industry. Group 1: Issuance Overview - The issuance of A-shares has been approved by the company's board and requires further approvals from shareholders, regulatory bodies, and exchanges before implementation [4][33]. - Jiangyao Holdings will subscribe to the shares for cash, constituting a related party transaction, with independent directors having reviewed the transaction [4][31]. - The maximum number of shares to be issued is 74,605,216, representing 13% of the company's total share capital before the issuance [6][23]. Group 2: Financial Details - The issuance price is set at 6.09 yuan per share, which is at least 80% of the average trading price over the previous 20 trading days [5][21]. - The total funds raised from this issuance are expected to be no more than 454,345,765.44 yuan, which will be used to supplement working capital and repay interest-bearing debts [6][25]. - The issuance will not affect the company's compliance with listing requirements regarding share distribution [34]. Group 3: Strategic Purpose - The issuance aims to consolidate the control of Jiangyao Holdings, which will hold approximately 19.23% of the company post-issuance, thereby optimizing the shareholding structure [14][58]. - The funds raised will enhance the company's financial strength and risk resistance, providing a solid foundation for future business expansion [16][58]. - The collaboration with Jiangyao Holdings is expected to improve market penetration and sales of existing products, leveraging their distribution channels [15][58]. Group 4: Market Context - The pharmaceutical industry is experiencing growth due to increased government support and rising healthcare demands driven by an aging population and higher health awareness [12][13]. - The CRO market in China is projected to grow significantly, with a compound annual growth rate of approximately 14% from 2022 to 2030, indicating strong future demand [13].